Peak Bio Statistics
Share Statistics
Peak Bio has 23.12M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 23.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.71K |
| FTD / Avg. Volume | 54.87% |
Short Selling Information
The latest short interest is 43.90K, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 43.90K |
| Short % of Shares Out | 0.19% |
| Short % of Float | 0.44% |
| Short Ratio (days to cover) | 0.35 |
Valuation Ratios
The PE ratio is -4398.92 and the forward PE ratio is -0.03.
| PE Ratio | -4398.92 |
| Forward PE | -0.03 |
| PS Ratio | 15.06 |
| Forward PS | 1.6 |
| PB Ratio | -0.31 |
| P/FCF Ratio | -1.16 |
| PEG Ratio | n/a |
Enterprise Valuation
Peak Bio Inc. has an Enterprise Value (EV) of 79.16M.
| EV / Earnings | -62862.53 |
| EV / Sales | 215.18 |
| EV / EBITDA | -58367.88 |
| EV / EBIT | -58367.88 |
| EV / FCF | -16.64 |
Financial Position
The company has a current ratio of 0.12, with a Debt / Equity ratio of -0.59.
| Current Ratio | 0.12 |
| Quick Ratio | 0.12 |
| Debt / Equity | -0.59 |
| Total Debt / Capitalization | -144.2 |
| Cash Flow / Debt | -0.44 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0.02%.
| Return on Equity (ROE) | 0% |
| Return on Assets (ROA) | 0% |
| Return on Capital (ROIC) | 0.02% |
| Revenue Per Employee | 61.31K |
| Profits Per Employee | -209.88 |
| Employee Count | 6 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -65.52% in the last 52 weeks. The beta is 1.78, so Peak Bio 's price volatility has been higher than the market average.
| Beta | 1.78 |
| 52-Week Price Change | -65.52% |
| 50-Day Moving Average | 0.1 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 42.6 |
| Average Volume (20 Days) | 3.12K |
Income Statement
In the last 12 months, Peak Bio had revenue of 367.88K and earned -1.26K in profits. Earnings per share was 0.
| Revenue | 367.88K |
| Gross Profit | 367.77K |
| Operating Income | -1.36K |
| Net Income | -1.26K |
| EBITDA | -1.36K |
| EBIT | -1.36K |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 381.65K in cash and 10.72M in debt, giving a net cash position of -10.34M.
| Cash & Cash Equivalents | 381.65K |
| Total Debt | 10.72M |
| Net Cash | -10.34M |
| Retained Earnings | -38.17M |
| Total Assets | 1.64M |
| Working Capital | -20.86M |
Cash Flow
In the last 12 months, operating cash flow was -4.76M and capital expenditures 0, giving a free cash flow of -4.76M.
| Operating Cash Flow | -4.76M |
| Capital Expenditures | 0 |
| Free Cash Flow | -4.76M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 99.97%, with operating and profit margins of -0.37% and -0.34%.
| Gross Margin | 99.97% |
| Operating Margin | -0.37% |
| Pretax Margin | -0.34% |
| Profit Margin | -0.34% |
| EBITDA Margin | -0.37% |
| EBIT Margin | -0.37% |
| FCF Margin | -1.29K% |
Dividends & Yields
PKBO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0% |
| FCF Yield | -894.58% |
Analyst Forecast
Currently there are no analyst rating for PKBO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -51.26 |
| Piotroski F-Score | 2 |